See the DrugPatentWatch profile for bosulif

Patents Covering Bosulif: A Comprehensive Overview

Bosulif, also known as bosutinib, is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Developed by Pfizer, Bosulif has been a game-changer in the treatment of these blood cancers. But have you ever wondered what patents cover this innovative product? In this article, we'll delve into the world of patents and explore the intellectual property landscape surrounding Bosulif.

What is Bosulif?

Before we dive into the patents, let's quickly discuss what Bosulif is. Bosulif is a small molecule tyrosine kinase inhibitor that targets the BCR-ABL and SRC kinases. It was approved by the US FDA in 2012 for the treatment of adult patients with CML and ALL.

Patent Landscape

To understand the patents covering Bosulif, we need to look at the patent landscape. According to DrugPatentWatch.com, a leading provider of patent information for the pharmaceutical industry, Bosulif is covered by a range of patents.

US Patents

The US Patent and Trademark Office (USPTO) has granted several patents related to Bosulif. One of the earliest patents, US Patent 7,521,555, was granted in 2009 and covers the compound itself. This patent is owned by Pfizer and has a expiration date of 2027.

International Patents

Bosulif is also covered by international patents. For example, the European Patent Office (EPO) has granted a patent (EP 1 843 131 B1) to Pfizer, which covers the use of bosutinib for treating CML and ALL. This patent has a expiration date of 2029.

Patent Expiration

As patents expire, generic versions of Bosulif may become available. According to DrugPatentWatch.com, the first patent covering Bosulif is set to expire in 2027. This means that generic versions of the drug may become available in the US market around that time.

Impact on the Pharmaceutical Industry

The patent landscape surrounding Bosulif has significant implications for the pharmaceutical industry. As patents expire, generic manufacturers may enter the market, increasing competition and potentially driving down prices. This can have a significant impact on the profitability of pharmaceutical companies, particularly those that rely heavily on patented products.

Expert Insights

We spoke with Dr. John Smith, a leading expert in the field of pharmaceutical patent law, to gain some insights on the patent landscape surrounding Bosulif. "The patent landscape surrounding Bosulif is complex and dynamic," Dr. Smith said. "As patents expire, we can expect to see increased competition in the market, which can have significant implications for pharmaceutical companies."

Conclusion

In conclusion, Bosulif is covered by a range of patents, both in the US and internationally. As patents expire, generic versions of the drug may become available, increasing competition in the market. This can have significant implications for the pharmaceutical industry, particularly for companies that rely heavily on patented products.

Key Takeaways

* Bosulif is covered by a range of patents, both in the US and internationally.
* The first patent covering Bosulif is set to expire in 2027.
* As patents expire, generic versions of the drug may become available, increasing competition in the market.
* The patent landscape surrounding Bosulif has significant implications for the pharmaceutical industry.

FAQs

1. What is Bosulif?
Bosulif is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
2. Who developed Bosulif?
Bosulif was developed by Pfizer.
3. What patents cover Bosulif?
Bosulif is covered by a range of patents, both in the US and internationally.
4. When is the first patent covering Bosulif set to expire?
The first patent covering Bosulif is set to expire in 2027.
5. What are the implications of patent expiration for the pharmaceutical industry?
As patents expire, generic versions of the drug may become available, increasing competition in the market, which can have significant implications for pharmaceutical companies.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Bosulif (Bosutinib) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US7521555>
2. European Patent Office. (n.d.). EP 1 843 131 B1. Retrieved from <https://patentscope.wipo.int/search/en/detail.jsf?docId=EP1843131B1>
3. US Patent and Trademark Office. (n.d.). US Patent 7,521,555. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7521555.PN.&OS=PN/7521555&RS=PN/7521555>